Since CSCs are believed to be responsible for tumor metastasis and relapse, interventional combinatorial approaches targeting MACC1 [48,49] and LGR5 [50,51] will potentially improve further targeted therapies for CRC patients to eradicate CSCs and prevent cancer recurrence and distant metastasis formation. The gene discussed is MACC1; the disease is neoplasm.